Skip to main content

Zanganeh Maky's Form 4 filing

Summit Therapeutics Inc. (SMMT) · filed Dec 13, 2023

Accession no.
0001599298-23-000103
Filed
Dec 13, 2023
Trade date
Dec 11-12, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $10.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Zanganeh MakyCIK 0001507650Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 11, 2023Common StockXIn-the-money exerciseAcquired+489,814$1.44+$705,332.16489,814Direct
Dec 12, 2023Common StockPPurchaseAcquired+5,000$2.07+$10,350494,814Direct
Dec 11, 2023Common StockXIn-the-money exerciseAcquired+315,681$1.58+$498,775.9824,889,479Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 11, 2023Common StockXIn-the-money exerciseDisposed−489,814$0.00$00Direct
Dec 11, 2023Common StockXIn-the-money exerciseDisposed−315,681$0.00$00Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)